Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?

Published:2018-10-09 Issue:17 Volume:19 Page:1857-1865
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Franczyk Beata¹,Gluba-Brzózka Anna²,Jurkiewicz Łukasz²,Penson Peter³^ORCID,Banach Maciej⁴^ORCID,Rysz Jacek¹

Affiliation:

1. Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Lodz, Poland

2. Department of Nephrology, Hypertension and Family Medicine, WAM Teaching Hospital, Lodz, Poland

3. School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK

4. Department of Hypertension, Medical University of Lodz, Lodz, Poland

Funder

not funded

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2018.1532501

Reference67 articles.

1. The Concept of the Polypill in the Prevention of Cardiovascular Disease

2. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

3. A strategy to reduce cardiovascular disease by more than 80%

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The CNIC-polypill (acetylsalicylic acid, atorvastatin, and ramipril), an effective and cost-saving secondary prevention strategy compared with other therapeutic options in patients with ischaemic heart disease;European Heart Journal Open;2024-03-01

2. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP);Progress in Cardiovascular Diseases;2023-07

3. Polypill as a Personalized Dosage Form: Production Technology (Review);Pharmaceutical Chemistry Journal;2023-04

4. Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A position paper of the International Lipid Expert Panel;Pharmacological Research;2022-09

5. The Era of Polypills in the Management of Cardiovascular Diseases: Are We There Yet?;Current Problems in Cardiology;2022-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3